Literature DB >> 24591486

PET/CT with sodium 18F-fluoride for management of patients with prostate cancer.

George M Segall1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24591486     DOI： 10.2967/jnumed.113.133546

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  5 in total

1.  The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer.

Authors:  Iain Murray; Sarah J Chittenden; Ana M Denis-Bacelar; Cecilia Hindorf; Christopher C Parker; Sue Chua; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-13       Impact factor: 9.236

2.  Prostate cancer: Better use of bone scans in prostate cancer.

Authors:  Steven M Larson
Journal:  Nat Rev Urol       Date:  2014-11-11       Impact factor: 14.432

Review 3.  Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

Authors:  M Picchio; P Mapelli; V Panebianco; P Castellucci; E Incerti; A Briganti; G Gandaglia; M Kirienko; F Barchetti; C Nanni; F Montorsi; L Gianolli; S Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-17       Impact factor: 9.236

4.  Sodium 18F-fluoride PET/CT of bone, joint, and other disorders.

Authors:  Hossein Jadvar; Bhushan Desai; Peter S Conti
Journal:  Semin Nucl Med       Date:  2015-01       Impact factor: 4.446

Review 5.  Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.

Authors:  Paola Mapelli; Maria Picchio
Journal:  Nat Rev Urol       Date:  2015-08-11       Impact factor: 14.432
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.